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Background: Recent studies analysing the trends in antipsychotic (AP) prescriptions for children and adolescents
have raised concerns regarding the influence of socioeconomic status. Previous findings have also shown variable
prescription rates for first-generation (FG) and second-generation (SG) APs.
Method: Our objectives were to assess the proportion of patients from low-income families receiving APs and the
most commonly prescribed APs in France. We conducted a descriptive analysis of AP drugs dispensed during a 1-year
period (July 1, 2013–June 30, 2014) in a northwestern region of France with 941,857 subjects less than 18 years old. All
data were extracted from an exhaustive, individual and anonymous social security database. We obtained each
subject’s socioeconomic status (by identifying their affiliation with a specific social security program) and also collected
sociodemographic data, drug type, prescribing and dispensing dates and amount, and prescriber type (e.g., hospital
physician, general practitioner, psychiatrist, paediatrician).
Results: There were two main novel findings. First, we found that the proportion of patients with AP prescriptions was
nearly ten times higher in low-income families than in the general population: 35.9% of CMU-C patients compared to
3.7% in all of Pays de la Loire (X2 = 7875.1, p < 0.001). Additionally, we found a higher rate of FGAP than SGAP
prescriptions (65% vs. 57%).
Conclusions: Our study suggests two types of AP misuse that could provide interesting targets for public healthcare
interventions.
First, our results strongly suggest an over-representation of patients from low-income families. Low-income families
primarily resided in areas with low physician density and appeared to receive drugs to treat their conditions more
frequently than other individuals. This increased prescription rate is a public health issue, potentially requiring political
action. Second, the use of FGAPs did not adhere to the latest recommendations for drug use in this population, and
this discrepancy should be addressed with informational campaigns targeted to medical practitioners.Background
Antipsychotic (AP) drugs are recommended for the treat-
ment for schizophrenia [1] and bipolar disorders [2] in
children and adolescents. These drugs are effective in
managing the core symptoms of these two diseases [1, 2].
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behaviour disorders, Tourette’s syndrome, post-traumatic
stress disorder, anorexia nervosa and autism spectrum
disorders [3, 4]. The recent literature regarding the pre-
scription of APs raises two main issues:
The first pertains to the use of first- and second-
generation APs. Considering the data on their efficacy
and side effects, the literature recommends a first-line
prescription of a second-generation AP (SGAP) and then
switching to another SGAP if necessary before consider-
ing a first-generation AP (FGAP) [1]. The choice of pre-
scription should balance the benefits and risks of thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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ence more side effects than adults [5, 6]. A recent study
showed that AP treatment is associated with increased
body weight and cardiometabolic side effects as well as
different side effect patterns [5]. The use of SGAPs is
now recommended, and longitudinal studies have shown
an increase in AP prescriptions in the last two decades
with a switch from FGAPs to SGAPs [7–9]. However,
some European studies, including those in France, have
found that FGAPs are still much prescribed in this
population, whereas in the U.S., the rate of FGAP pre-
scriptions among youth is now very low [4, 10].
The second issue is related to the patients’ socioeco-
nomic status (SES). Very few studies have explored the
influence of socioeconomic/residential status on AP pre-
scription rates. Existing research has focused on rural vs.
urban inhabitants [11, 12] and has found no correlations
between these parameters and AP prescriptions. Two re-
cent studies on this topic yielded conflicting results. One
study reported that AP prescriptions were more com-
mon among people from low-income areas in the UK
[13], whereas the second study failed to find an associ-
ation between AP consumption by youth and the rate of
welfare benefits [14]. These inconsistent findings may
have occurred because the authors correlated the overall
rate of AP prescriptions with welfare benefits of geo-
graphic locations rather than individual welfare data.
The effect of SES might be more related to individual
factors than to the geographic location.
To study these two issues, we conducted a descriptive
analysis of drugs dispensed during a 1-year period (July
1, 2013–June 30, 2014) in an exhaustive study of a
northwestern region of France with 3,658,000 inhabi-
tants, including 941,857 subjects younger than 18 years
old whose socioeconomic conditions were known.
Methods
Data source and population sample
We conducted an observational study of a retrospective
cohort using a healthcare database that included infor-
mation on subjects living in one area (Pays de la Loire)
with five different counties (Loire Atlantique, Maine et
Loire, Mayenne, Sarthe, and Vendée).
The data were extracted from one database (datamart
de Consommation Inter Regimes, DCIR) that was part of
the French healthcare insurance database (Système Na-
tional d’Information Inter Régimes de l’Assurance Mala-
die, SNIIR-AM), which contains all of the information
from the main insurance schemes in France; the SNIIR-
AM covers salaried workers, farm workers, non-salaried
workers (i.e., craftsmen and tradesmen), and a few other
special groups (i.e., teachers, policemen, and armed
forces). Affiliation with one of these schemes is mandatory
(i.e., persons cannot be outside of the database). TheDCIR database is an exhaustive, individual and anonym-
ous healthcare database that includes all information on
refunded healthcare claims. Individuals cannot purchase
any of the included drugs without a pharmacist’s report of
this prescription being documented in the DCIR. There-
fore, it is the main point of access for information on drug
consumption by a large group of individuals. As with all
subjects, individuals younger than 18 years have their own
anonymous health service code, which is a lifetime code
that uniquely identifies each resident.
Our population sample was composed of all children
and adolescents younger than 18 years old at the end of
the study period (July 1, 2013, to June 30, 2014) who were
living in the Pays de la Loire area (northwestern France,
3.658 million inhabitants in 2013 [15]). All characteristics
of the youth who received at least one dispensation of
psychotropic drugs were obtained (n = 17.198).
Psychotropic drug selection process in the database
Drugs were identified using the International Non-
proprietary Name (INN) and categorized using the Ana-
tomical Therapeutic Chemical (ATC) classification sys-
tem [16], which is commonly applied in epidemiologic
studies. We selected APs, which are a subcategory of
N05, the N05A group. We also added valproic acid
(N03AG01) and valpromide (N03AG02). The total list of
drugs included was as follows: Chlorpromazine, Levo-
mepromazine, Cyamemazine, Valproic acid, Valpromide,
Periciazine, Pipamperone, Haloperidol, Flupentixol,
Zuclopenthixol, Pimozide, Loxapine, Clozapine, Olanza-
pine, Quetiapine, Sulpiride, Tiapride, Amisulpride, Ris-
peridone, Aripiprazole, and Paliperidone.
Valproic acid and valpromide are commonly used for
their AP effects by prescribers in general practice in
France (even if they are off-label), and we chose to include
them after a consensus meeting with all the authors of this
article (i.e., OB, CC, PH, CV, PJ).
Study measures
We collected information on participants’ sociodemo-
graphic data (gender, county, affiliated healthcare insur-
ance scheme, age, and CMU-C status). Couverture
Maladie Universelle Complémentaire (CMU-C) is a sup-
plemental universal public insurance coverage scheme for
low-income persons. The criteria for accessing the CMU-
C include an income less than 721 euros/month for a
single individual, adding 250 euros for each member of
the family. Affiliation with CMU-C is considered a poverty
threshold in France. Therefore, CMU-C status defines the
group of people under the poverty threshold in France.
We created 5 age categories: 0–4, 5–9, 10–14 and 15–
17 years old.
Regarding medications, we collected the type of drug
dispensed (INN and ATC code (5th level)), the date of
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pensations, and the prescriber type (e.g., hospital phys-
ician, general practitioner, psychiatrist, paediatrician).
Our database granted access to all drugs dispensed and
reimbursed in a pharmacy (and thus all prescriptions). We
were able to determine how many different dispensations
each patient had received during the study period. In
France, drugs are provided to patients in complete blister
cards (with a pre-defined number of slots), not by pills.
Patients are usually given 1 month of treatment per dis-
pensation (with the number of complete blister cards cal-
culated accordingly). Therefore, patients typically receive
extra pills, which may represent more than a 1-month
supply. We determined the treatment duration for each
subject by accessing the number of different months of
dispensation in the follow-up for each drug. The month of
dispensation was obtained to determine whether treat-
ment was chronic (continuous variable), and we consid-
ered subjects receiving at least 6 months of dispensations
as chronic users, which was consistent with the method-
ology of a previous study using this database [14].
Finally, it was difficult to determine the type of hospital
practitioner prescribing APs. All prescriptions from physi-
cians working in a hospital are dispensed with the unique
identification number of the hospital. Currently, the only
way to access information on the type of hospital practi-
tioner is to access the actual prescription, which would
have provided the name and medical speciality of the
physician; however, this approach was not possible in our
study for ethical reasons (lack of anonymity).
We also searched for national data regarding the gen-
eral population. We focused on the number of inhabi-
tants [15], proportion of CMU-C patients [17] and
medical density in the study region [18].
Statistical analysis
Statistical analyses were performed using SAS Enterprise
software version 4.3, and the detailed data were ex-
tracted and analysed by individuals who manage the
healthcare insurance database according to the national
commission for liberty and informatics (CNIL) laws.
A descriptive analysis was performed for sociodemo-
graphic and drug prescription data. We also calculated
the proportion of AP prescriptions in comparison with
general population data.
A proportions test based on chi2 was performed to
compare the prevalence of CMU-C patients in our sam-
ple with that of the general population.
Results
Prescription overview
Among all patients in the Pays de la Loire region, 0.33%
(2,897 children and adolescents under 18 years old) had
an AP prescribed and dispensed during the observationperiod (see Table 1). Half of these prescriptions were for
patients aged 13 years or younger (48%). Prescriptions
increased with age and were higher in boys than in girls
(0.47 in boys and 0.18 in girls).
Our results also showed that the overall AP prescription
rate differed by county. Two counties were above the aver-
age prescription rate (0.33%): Mayenne (0.72%) and Maine
et Loire (0.40%). Some rates, such as AP prescriptions for
boys 5 to 9 years old in Mayenne vs. all areas (0.98 com-
pared to 0.30), were of particular importance. The results
in Mayenne were higher than the average for all sex and
age subgroups; for example: 0.52 vs. 0.24% for girls aged
10–14 years and 1.75 vs 0.74% for boys aged 10–14 years.
We present AP prescription rates by county with medical
density in Table 2 (using data from the Conseil National
de l’Ordre des Medecins) [18].
CMU-C-affiliated population
The proportion of individuals affiliated with CMU-C in
our study was approximately 1/3 of our population
(35.9%). When compared to the rates in the general
population in Pays de la Loire, Chi2 comparison tests
showed a higher proportion of CMU-C patients in our
sample (X2 = 7875.1, p < 0.001). The results were similar
in all counties (see Table 3). CMU-C affiliation was
higher in families with children over 5 years: 22.7% for
ages 0–4, 36.3% for ages 5–9, 35.5% for ages 10–14 and
36.7% for ages 15–17 years.
AP-specific medication data
Regarding single prescriptions, FGAPs were prescribed
more frequently than SGAPs (65% vs. 57%). The ratio of
FGAPs to SGAPs decreased with age, at 86% vs. 32% for
subjects 0–4 years old and 63% vs. 61% for subjects 15–
17 years old. In our study, 23% of subjects received both
FGAPs and SGAPs. The overall data for all prescriptions
(single and combination) are presented in Table 4.
The most commonly prescribed APs were cyamema-
zine and risperidone, totalling 1,379 and 1,303 prescrip-
tions, respectively. Aripiprazole was the third-most
prescribed AP, with only 207 prescriptions.
Regarding the duration of cyamemazine treatment,
33% of children/adolescents (463 of 1,379) had only a 1-
month dispensation, and 27% (366 of 1 379) had 6 sep-
arate months with one or more dispensations per year.
For risperidone, 18% of children/adolescents (230 of
1,303) had only one month of dispensed drugs, and 41%
(532 of 1,303) had 6 separate months with one or more
dispensations per year.
Regarding the type of prescribers, hospital physicians
comprised 73.2% of the total. For 46.3% of the patients,
these doctors were their only prescriber. General practi-
tioners prescribed 11.4% of the patients’ prescriptions
during the study period (results are in Table 5).
Table 1 Raw 2013 prevalence rates of antipsychotic delivery by age and sex in Pays de la Loire and its 5 counties
Gender Age
(years)
Loire Atlantique Maine et Loire Mayenne Sarthe Vendée Pays de la Loire (All)
n % Pop n % Pop n % Pop n % Pop n % Pop 85 n % Pop
MALE 0–4 4 0.01 12 0.05 9 0.09 4 0.02 - - 29 0.02
5–9 89 0.21 105 0.39 104 0.98 35 0.19 29 0.14 362 0.30
10–14 221 0.52 233 0.89 183 1.75 114 0.63 123 0.62 874 0.74
15–17 216 0.88 170 1.14 114 1.93 99 0.93 108 0.98 707 1.05
Total 530 0.35 520 0.55 410 1.10 252 0.38 260 0.36 1972 0.47
FEMALE 0–4 5 0.01 4 0.02 2 0.02 3 0.02 1 0.01 15 0.01
5–9 13 0.03 25 0.10 15 0.15 15 0.08 11 0.06 79 0.07
10–14 61 0.15 97 0.38 52 0.52 33 0.19 23 0.12 266 0.24
15–17 113 0.48 99 0.68 44 0.80 61 0.58 57 0.53 374 0.57
Total 192 0.13 225 0.25 113 0.32 112 0.18 92 0.13 734 0.18
ALL 0–4 9 0.01 16 0.03 11 0.05 7 0.02 1 <0.01 44 0.02
5–9 102 0.12 130 0.25 119 0.57 50 0.14 40 0.10 441 0.19
10–14 282 0.34 330 0.64 235 1.15 147 0.41 146 0.38 1140 0.50
15–17 329 0.68 269 0.91 158 1.38 160 0.75 165 0.75 1081 0.82
Total 722 0.24 745 0.40 523 0.72 364 0.28 352 0.25 2706 0.33
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This study presented two main novel results. First, we
found that the proportion of patients with APs was al-
most ten times higher in low-income families than in
the general population: 35.9% of low SES patients com-
pared to 3.7% in all of Pays de la Loire (X2 = 7875.1, p <
0.001). In addition, we found a higher rate of FGAP than
SGAP prescriptions (65% vs. 57%).
In general, our sample is comparable to those of other
recent French studies, as our overall AP prescription
rate was 0.33% (0.47 in boys and 0.18 in girls) for pa-
tients under 18 years old. Three major studies on the
use of AP medications have been conducted using the
French healthcare insurance database. In 2004, a study
was conducted in two different regions, showing that
0.3% of patients used APs and that the rates increased
with age [19, 20]. Using a different methodology and a
random sample (1%) from the 2010 national database,
another study reported an overall AP prescription rate
of approximately 0.27–0.33% (0.35–0.45% for boys) [21].
A recent study examined a random representative sam-
ple of the French population (1%) extracted from the
healthcare insurance database from 2006 to 2013 [14]
and found an overall AP prescription rate of 0.49% for
patients under 25 years old, 0.47% for patients betweenTable 2 Medical facility density (/100 000 inhabitants) and raw antip
(n = 3 658 000) from July 1st 2013 to June 30th 2014
Mayenne Vendée
Medical practionner density 179.8 201.3
Rate of AP prescriptions 0.72 0.2511 and 15 years old, and 0.26% for patients between 6
and 10 years old.
These results are also consistent with recent studies in
Europe. For example, a study in Germany used a similar
method involving an exhaustive data source from a large
area and found that the rate of AP prescriptions in 2012
was 0.33% and increased with age [13, 22]. Compared to
older studies and those with different methodologies
(smaller, non-exhaustive samples or random partial ex-
tractions of a large population), our results are within
the mean range of data from Western countries, which
show prevalences of APs ranging from 0.08% in Italy
[23] to 0.76% in the U.S. [24]. Our rates in France are
lower than those in the U.S., with the most recent
French data reporting AP use in 2006 and 2010 by
0.14% and 0.11% of younger children, 0.85% and 0.80%
of older children, 1.10% and 1.19% of adolescents, and
0.69% and 0.84% of young adults [21].
Socioeconomic status
The results regarding SES are important and similar in all
counties (see Table 3). To our knowledge, this type of data
has not been presented in previous studies. Although these
results differ from comparable French [14] and Canadian
[12] studies, previous authors compared the global rate ofsychotic prescription rate in all Pays de la Loire department
Sarthe Maine et Loire Loire Atlantique
212 283.7 308.3
0.28 0.40 0.24
Table 3 Patients with CMU-C in our sample and in general population
Patients with CMU-C
affiliation (n)
Patients with NO CMU-C
affiliation (n)
Total Proportion of individuals with CMU-C
in general population (%)
95% CI/Chi2 p
Total Pays de la Loire
Region
972 1734 2706 3.7 0.34–037/7875.1 <0.001
Loire Atlantique 250 472 722 4.6 0.31–0.38/1476.4 <0.001
Maine et Loire 255 490 745 4.9 0.31–038/1368.8 <0.001
Mayenne 190 333 523 4.2 0.32–0.40/1333.8 <0.001
Sarthe 132 232 364 6.2 0.31–041/560.5 <0.001
Vendée 122 230 352 3.1 0.29–0.39/1156.6 <0.001
Comparison test with chi2. All p are 0.20 10−16
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study included each parent’s CMU-C affiliation. Our ap-
proach provides a different perspective and suggests, by in-
corporating individual status, that being from a low-income
family instead of simply living in a low-income area may be
associated with increased prescription of APs.
In the same vein, we also found that the geographical
distribution of AP users was not homogeneous and was
greater in counties with the lowest medical density com-
pared to those with a higher medical density (see
Table 2). The ratio of medical facilities in the entire re-
gion was 272.7/100,000 inhabitants, which is slightly
lower than the national density of 299.7/100,000 [18].
Moreover, the county with the lowest rate of AP pre-
scriptions was Loire Atlantique, which also has the high-
est density of medical facilities. In contrast, the highest
rate (0.72) was found in Mayenne, where the medical
density is the lowest. These data suggest that individuals
with greater medical access receive fewer AP prescrip-
tions (see Table 2).
We found conflicting evidence in the literature regard-
ing the impact of residence on AP prescriptions. A studyTable 4 Type of antipsychotic and thymoregulator prescribed by ag
to June 30, 2014
Age
0–4 y n = 44 5–9 y n = 441
Antipsychotic type and combination n % n %
SGAP single prescription 6 13.6 133 30.2
FGAP single prescription 36 81.8 237 53.7
FGAP (only usedTourette) - - 5 1.1
Valproate or Valpromide - - 3 0.7
SGAP + FGAP 2 4.5 62 14.1
SGAP+ Valproate or Valpromide - - 1 0.2
FGAP+ Valproate or Valpromide - - - -
Various combination - - - -
FGAP/SGAP ratio 86.3/18.1 68.9/44.5
SGAP second generation antipsychotic, FGAP first generation antipsychotic, Tourette
TGAP/SGAP ratio encompass all FGAP or SGAP, even if it is co-prescription (relatedfrom Taiwan found that AP prescriptions for patients
aged 18 years or under were more frequent in suburban
areas than in urban and rural areas [11], although this
relationship was not found in a Canadian study [12].
However, Verdoux and colleagues found an increase in
the level of AP prescriptions in areas with a low density
of health facilities for children under 10 years old and in
areas with low socioeconomic resources (global CMU-C
affiliation rate in the area) for adolescents aged 16–20
years [14]. These conflicting results can be explained,
again, by their use of data from large groups rather than
from individually oriented data.
However, we could not determine a correlation be-
tween the density of medical facilities and access to
health resources because of imprecisions in our data.
Access to health care facilities depends on the exact part
of the county where the patient resides (e.g., a family liv-
ing in southern Mayenne may have better access to the
University Hospital of Angers in Maine et Loire than
some people in the extreme south of the Angers area).
Another limitation of our study is that our data could
not determine the purpose of the prescription or thee in all Pays de la Loire areas (n = 3 658 000) from July 1, 2013
Total n =
270610–14 y n = 1140 15–17 y n = 1081
n % n % n %
392 34.4 369 34.1 900 33.3
447 39.2 390 36.1 1110 41.0
3 0.3 3 0.3 11 0.4
8 0.7 19 1.7 30 1.1
262 23.0 252 23.3 578 21.5
8 0.7 8 0.8 17 0.6
2 0.2 8 0.8 10 0.3
18 1.2 32 3.0 50 1.8
63.2/58.6 60.3/58.2 65.1/57.1
AP used exclusively in Tourette syndrome in France (pimozide)
to an amount of prescription more then a number of individuals)
Table 5 Type of prescribers (alone or associated with others) in all Pays de la Loire regions (n = 3 658 000) for antipsychotic
prescriptions from July 1, 2013 to June 30, 2014
Specialty Only prescriber for a particular
patient
Other prescribers are in charge of the
patient
Total n = 2706
n % n % n %
Hospital any type (mostly paediatricians and psychiatrists) 1252 46.3 729 26.9 1981 73.2
General Practice 309 11.4 581 21.5 890 32.9
Psychiatrist 250 9.2 257 9.5 507 18.7
Paediatrician 15 0.6 26 1.0 41 1.5
Other 9 0.3 52 1.9 61 2.3
No Info 42 1.6 164 6.1 206 7.6
Table is to read by line, and not per columns (for example 507 patients (18.7% of our 2 706 patient’s sample had prescription by a psychiatrist, among them 250
had only one prescriber, and 257 had more then one)
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onymous data prohibit access to these data in French in-
surance databases. Accordingly, we could not link AP
prescriptions to specific diagnoses.
The higher level of AP prescriptions among children
and adolescents from low-income families can be ex-
plained by two hypotheses:
1. Patients from low SES families are known to exhibit
more psychiatric disorders, especially those
associated with behavioural disturbances [25, 26].
This correlation is stronger for anxiety and mood
disorders (which may be associated with behavioural
disturbances in youth) and ADHD than for diseases
such as autism, schizophrenia and Tourette’s
syndrome [25, 26], which are core indications for
AP prescription. Moreover, a higher incidence of
behavioural problems has been found among
preschool children from low SES families [27] and
adolescents living in poverty [28]. Unfortunately, we
were not able to verify this hypothesis, as we could
not determine diagnoses in our sample.
2. The second hypothesis is related to the specific
situations regarding child and adolescent psychiatry
in France. A large percentage of child and
adolescent psychiatrists in France do not commonly
prescribe psychotropic medications, particularly APs.
This practice is associated with the strong
psychoanalytic culture in France along with a lack of
current scientific knowledge about medications.
Most of our colleagues consider themselves
psychotherapists. Therefore, a psychiatrist may be
more likely to prescribe medications for behavioural
reasons than for developmental disorders (e.g.,
autism spectrum disorders, schizophrenia [29],
Tourette’s). Additionally, there are few
hospitalizations that occur for child and adolescent
psychiatric disorders due to the limited number of
beds in France for emergencies or short periods(13.5/100,000 inhabitants), especially in Pays de la
Loire (7/100 000 in Loire Atlantique, 9 in Maine et
Loire and 12 in Sarthe, with other counties having
only long-term hospitalizations, which are more
similar to boarding school) [30]. There is also a lack
of non-medical psychiatric healthcare professionals
such as clinical psychologists, as in contrast to
psychiatrists, psychologists’ interviews are not
reimbursed by social security [15].
These hypotheses may be synergistic. APs are frequently
used to treat behavioural issues and may provide a quick
solution to complex situations that would benefit from in-
dividual and family evaluation and support. When patients
from low SES families exhibit more behavioural disorders,
they encounter psychiatrists with few therapeutic options
other than medications. Patients from higher SES families
may be more likely to seek psychologists in private prac-
tice or re-educators (whose visits are not free).
Further studies that evaluate the specific level of care
(medical and social) and the exact purpose for AP pre-
scriptions are necessary to confirm this hypothesis.
FGAPs vs. SGAPs
The rates of FGAP compared to those of SGAPs were
particularly high among younger patients: 86% vs. 32%,
respectively, for ages 0–4 years and 69% vs. 44%, re-
spectively, for ages 5–9 years. Remarkably, the rates
remained high in children 10 to 13 years old (39.2%
FGAP vs. 34.4% SGAP) and adolescents from 15 to
17 years old (36.1% FGAP vs. 34.1% SGAP). Indeed, re-
cent AMMs (Market Release Authorizations) for SGAPs
have made them available to 13- to 15-year-old patients
instead of only 18-year-old patients (for aripiprazole,
olanzapine and risperidone). Moreover, in 2007, an
AMM was obtained for the use of risperidone in 5-year-
olds for behavioural disorders involving intellectual
deficiency. Therefore, SGAPs could have been prescribed
more extensively.
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reported in the most recent comparable studies in
France [14, 31] for all ages, with rates of FGAPs vs.
SGAPs for infants, children and adolescents of 86.3% vs.
53.6%, 68.9% vs. 41.5% and 83.9% vs. 58.8%, respectively
[14]. However, these previous studies involved a repre-
sentative national sample that did not reflect regional
disparities (see explanation for Pays de la Loire above).
This high level of FGAP prescription may be harmful
because the side effect profile of APs differs drastically,
especially in the paediatric population [6, 32]. In other
countries, longitudinal studies have shown an increase
in AP prescriptions in the last two decades as well as a
switch from FGAPs to SGAPs [7–9].
The high use of cyamemazine, which was the most
commonly prescribed AP in our study, is likely related
to French habits. In France, cyamemazine is mainly used
as a sedative and anxiolytic drug, despite its poor toler-
ance due to metabolic syndrome as well as its limited
AP effects [33]. Cyamemazine was also originally devel-
oped by a French laboratory and was marketed heavily
in the 1990s. However, cyamemazine has a low affinity
for dopaminergic receptors and therefore poor AP activ-
ity. The sedative effects of cyamemazine are mediated
through its 5HT2A activity [34]. The main scientific lit-
erature regarding cyamemazine has investigated its effi-
cacy in treating benzodiazepine withdrawal, particularly
for alcoholic patients (for a review, see [35]). The very
high level of cyamemazine use is likely related to a lack
of knowledge of the efficacy and side effects as well as to
prescribers’ habits. The lack of knowledge about new
SGAPs and their AMMs for younger patients may also
be a reason for the low level of SGAP prescription, par-
ticularly during adolescence. Our results are comparable
with those of previous studies showing a high rate of
cyamemazine use in France [14].
Conclusion
Our epidemiological study in an exhaustive population
demonstrated that the consumption of APs is concern-
ing, occurring in 33 children and adolescents out of
10,000. This overall rate is admissible, but the qualitative
analysis suggests a few concerning findings that should
be addressed.
There was a misuse of APs, with an excessive number
of FGAP prescriptions, especially for cyamemazine. This
practice appears to be related to a lack of knowledge re-
garding the efficacy and side effects of this drug. The
FGAP/SGAP ratio in northwest France was higher than
the national mean [14] and was not compliant with the
latest recommendations for drug use in this population.
This discrepancy should be addressed through an infor-
mation campaign directed towards medical practitioners
and in the teaching of medical students. As our workwas conducted with the French National Health Insur-
ance organization, a full partnership to undertake this
type of campaign is already in place.
Despite the lack of information regarding the reasons
for prescription, our results strongly suggest an over-
representation of patients from low SES families in our
sample of youth receiving APs. These patients were
mainly living in areas with a low physician density and
received drugs to treat their conditions more often than
other individuals. Therefore, it is important to communi-
cate these findings to medical practitioners, and political
action to address these discrepancies may be necessary.
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